MARLBOROUGH, Mass., Oct. 23, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced key data that willbe presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in Denver, on October 29 - November 2.
Other presentations of interest include five-year follow-up data from the Continued Access to PROTECT AF (CAP) Registry, which is related to long-term event rates for LACC with the WATCHMAN Device, and a sub-analysis from the PLATINUM Diversity study addressing predictors of increased risk for cardiac events following percutaneous coronary intervention in minority women.
"We look forward to continuing the important dialogue around the WATCHMAN LAAC Device as an alternative option to long-term warfarin therapy for patients with non-valvular atrial fibrillation who are seeking another treatment to reduce their risk of stroke," said Professor Ian Meredith, M.D., executive vice president and global chief medical officer, Boston Scientific. "Additionally, presentations around our drug-eluting innovations, structural heart technologies and our therapeutic options addressing chronic total occlusions will help provide clinicians with insights that can be applied to their practice of treating coronary and peripheral artery disease."
PRESENTATIONS OF INTEREST (listed chronologically)
Monday, October 30
Tuesday, October 31
Thursday, November 2
All presentations are listed in Mountain Daylight Time and will take place at the Colorado Convention Center. For more information, visit Boston Scientific at booth #2018.
The company will also host an investor event and webcast on Monday, October 30, from noon – 1 p.m. MDT to provide a business update and answer questions from investors about the Boston Scientific cardiovascular portfolio. The event will be accessible at www.bostonscientific.com/investors. A replay of the webcast will be accessible at www.bostonscientific.com/investors beginning approximately one hour following the completion of the event.
In the U.S., the Lotus Valve System, ACURATE neo and the Eluvia Stent System are investigational devices and are not available for sale.
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
CONTACTS: Trish Backes Media Relations Boston Scientific Corporation (651) 582-5887 (office) Trish.Backes@bsci.com
Susie Lisa, CFA Investor Relations Boston Scientific Corporation (508) 683-5565 (office) email@example.com
View original content:http://www.prnewswire.com/news-releases/boston-scientific-announces-scheduled-presentations-at-transcatheter-cardiovascular-therapeutics-2017-300541397.html
SOURCE Boston Scientific
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All